Company Filing History:
Years Active: 2024
Title: Björn Steinmann: Innovator in Antibody Development
Introduction
Björn Steinmann is a notable inventor based in Frankfurt-am-Main, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies.
Latest Patents
Steinmann holds a patent for a humanized anti-IL-1R3 antibody and methods of use. This innovative antibody specifically binds to IL-1R3 and comprises an antibody heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2. The patent also describes a pharmaceutical composition that includes this antibody along with a pharmaceutically acceptable diluent, carrier, or excipient. Furthermore, the antibody is intended for use in treating diseases or disorders, particularly autoimmune or autoinflammatory conditions.
Career Highlights
Björn Steinmann is currently employed at Sanofi Biotechnology, where he continues to advance his research and development efforts in the field of therapeutic antibodies. His work is pivotal in addressing various medical challenges through innovative solutions.
Collaborations
Steinmann collaborates with talented colleagues, including Christian Lange and Ziyu Li, who contribute to the success of their projects at Sanofi Biotechnology.
Conclusion
Björn Steinmann's work in antibody development exemplifies the innovative spirit of modern biotechnology. His contributions are vital in the ongoing quest to develop effective treatments for complex diseases.